首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

2103080

全球視神經脊髓炎患者人數分析與預測（2026-2035 年）

Global Neuromyelitis Optica Patient Population Analysis and Forecast, 2026 - 2035

出版日期: 2026年07月17日 | 出版商:

Knowledge Sourcing Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

對全球視神經脊髓炎患者數量的分析表明，在預測期（2026-2035 年）內，預計會出現較高的複合年成長率。

視神經脊髓頻譜疾病（NMOSD）是一種罕見的自體免疫中樞神經系統發炎性疾病，主要涉及視神經和脊髓。其特徵是反覆發作的視神經炎、橫貫性脊髓炎和腦幹炎症，若不及時治療，往往會導致永久性神經功能障礙。抗體檢測技術的進步顯著提高了疾病的識別率，並有助於將其與多發性硬化症區分開來，從而能夠更準確地識別全球患者。隨著大量創新生物製藥的上市，患者群體分析對於醫療保健規劃、臨床試驗招募、市場預測和保險報銷決策變得日益重要。

患者群體分析能夠全面深入地揭示疾病的流行情況、發病率、確診患者數量、人口統計學特徵、抗體狀態、疾病嚴重程度、地理分佈以及長期流行病學預測。這些分析有助於製藥公司、生技公司、醫療服務提供者、政策制定者、研究人員和投資者評估市場機會並最佳化治療策略。

市場促進因素

提高診斷準確性

市場成長的主要驅動力之一是先進診斷技術的廣泛應用，特別是高靈敏度的AQP4抗體檢測和改進的磁振造影（MRI）技術。這些進步顯著縮短了診斷延遲，並提高了區分視神經脊髓炎譜系障礙（NMOSD）和多發性硬化症的準確性。

早期診斷能夠更準確地識別患者，擴大流行病學資料庫，並有助於改善疾病的長期監測。

對該疾病的認知提高

更新的診斷標準和標靶生物製藥的出現顯著提高了神經科醫生和醫療保健專業人員對該疾病的認知。加強教育活動和推廣罕見疾病支持項目，促使患者更早轉診至醫療機構，並提高了全球範圍內的診斷率。

人們日益增強的這種意識不斷促使患者登記系統進一步改進，流行病學研究也得到加強。

病人登記擴容

國內外的罕見疾病登記處正在產生越來越全面的患者人口統計、疾病進展、治療模式和長期結果數據。

這些註冊登記可以改善患者識別，加快臨床試驗的招募，幫助產生真實世界數據 (RE)，並提高未來人口預測的準確性。

精準醫療的需求日益成長

開發標靶治療需要根據抗體狀態、年齡、疾病嚴重程度和臨床表現型對患者亞群進行詳細了解。

透過分析患者群體，製藥公司可以估算合格治療條件的人群，並最佳化其精準醫療的商業化策略。

市場限制因素

被歸類為罕見疾病

與更常見的神經系統疾病相比，NMOSD 仍然是一種相對罕見的神經系統疾病，導致全球患者群體有限，流行病學資料小規模。

診斷方面的區域差異

已開發市場和新興市場在抗體檢測、神經科專科護理和先進診斷基礎設施的取得方面存在顯著差異，導致某些地區的診斷往往不足。

流行病學資料的變異性

診斷標準、登記系統範圍、醫療報告系統和調查方法的差異會導致各國估計值出現差異。

流行病學和患者族群調查結果

NMOSD 是一種罕見疾病，但由於診斷技術的進步和人們意識的提高，全球對患者的識別工作正在取得進展。

近期全球流行病學研究估計，視神經脊髓炎譜系疾病（NMOSD）的盛行率約為每10萬人0.07至10例，年發生率約為每10萬人0.03至0.88例，但這些數據會因地理區域、種族和調查方法而異。報告的盛行率最高的是非洲加勒比人和某些亞洲人群，而白種人群的盛行率通常較低。

確診病例中女性居多，男女比例通常大於8:1，尤其是AQP4抗體陽性的患者。發病年齡多為中年，但兒童病例和晚髮型病例也日益增加。

隨著抗體檢測的普及、醫生意識的提高以及罕見疾病監測計劃的完善，預計在預測期內，確診患者的數量將穩步成長。

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune inflammatory disease of the central nervous system that primarily affects the optic nerves and spinal cord. The disease is characterized by recurrent episodes of optic neuritis, transverse myelitis, and brainstem inflammation, often resulting in permanent neurological disability if left untreated. Advances in antibody-based diagnostics have significantly improved disease recognition and differentiation from multiple sclerosis, leading to more accurate identification of patients worldwide. As innovative biologic therapies continue to enter the market, patient population analysis has become increasingly important for healthcare planning, clinical trial recruitment, market forecasting, and reimbursement decision-making.

Patient population analysis provides comprehensive insights into disease prevalence, incidence, diagnosed patient populations, demographic characteristics, antibody status, disease severity, regional distribution, and long-term epidemiological forecasts. These analyses enable pharmaceutical companies, biotechnology firms, healthcare providers, policymakers, researchers, and investors to evaluate market opportunities and optimize treatment strategies.

Market Drivers

Increasing Diagnostic Accuracy

One of the primary drivers of market growth is the widespread adoption of advanced diagnostic technologies, particularly highly sensitive AQP4 antibody assays and improved magnetic resonance imaging (MRI). These advances have significantly reduced diagnostic delays and improved differentiation between NMOSD and multiple sclerosis.

Earlier diagnosis enables more accurate patient identification, expanding epidemiological databases and supporting better long-term disease monitoring.

Growing Disease Awareness

Awareness among neurologists and healthcare providers has increased substantially following the publication of updated diagnostic criteria and the availability of targeted biologic therapies. Improved education initiatives and rare disease advocacy programs have contributed to earlier referrals and higher diagnosis rates worldwide.

Greater awareness continues to strengthen patient registry development and epidemiological research.

Expansion of Patient Registries

National and international rare disease registries are generating increasingly comprehensive data regarding patient demographics, disease progression, treatment patterns, and long-term outcomes.

These registries improve patient identification, facilitate clinical trial recruitment, support real-world evidence generation, and strengthen future population forecasting.

Rising Demand for Precision Medicine

The development of targeted therapies requires detailed understanding of patient subgroups based on antibody status, age, disease severity, and clinical phenotype.

Patient population analysis enables pharmaceutical companies to estimate eligible treatment populations and optimize commercialization strategies for precision therapies.

Market Restraints

Rare Disease Status

NMOSD remains a relatively uncommon neurological disorder, resulting in a limited global patient population and smaller epidemiological datasets compared with more common neurological diseases.

Regional Differences in Diagnosis

Access to antibody testing, specialist neurological care, and advanced diagnostic infrastructure varies considerably between developed and emerging markets, leading to underdiagnosis in certain regions.

Variability in Epidemiological Data

Differences in diagnostic criteria, registry coverage, healthcare reporting systems, and study methodologies may produce variability in prevalence and incidence estimates across countries.

Epidemiology and Patient Population Insights

Although NMOSD is a rare disease, improvements in diagnosis and awareness have resulted in increasing identification of patients worldwide.

Recent global epidemiological studies estimate that NMOSD prevalence ranges from approximately 0.07 to 10 cases per 100,000 population, while annual incidence ranges from approximately 0.03 to 0.88 cases per 100,000 population, depending on geographic region, ethnicity, and diagnostic methodology. The highest prevalence has been reported in Afro-Caribbean and certain Asian populations, whereas lower prevalence has generally been observed in White populations.

Women account for the majority of diagnosed cases, particularly among AQP4 antibody-positive patients, with female-to-male ratios frequently exceeding 8:1. Disease onset most commonly occurs during middle adulthood, although pediatric and late-onset cases are increasingly recognized.

The diagnosed patient population is expected to increase steadily throughout the forecast period as access to antibody testing expands, physician awareness improves, and rare disease surveillance programs become more comprehensive.

Technology and Segment Insights

The global NMOSD patient population analysis market can be segmented by disease subtype, antibody status, age group, gender, disease stage, data source, end user, and geography.

By disease subtype, the market includes AQP4 antibody-positive NMOSD, myelin oligodendrocyte glycoprotein (MOG)-associated disease, and seronegative NMOSD. AQP4-positive patients represent the largest diagnosed patient segment.

By antibody status, patient populations are categorized into AQP4-positive, MOG-positive, and double-seronegative groups, supporting personalized treatment selection and clinical research.

By age group, the market includes pediatric, adult, and elderly patient populations. Adult patients account for the largest proportion of diagnosed cases.

By disease stage, the market includes newly diagnosed patients, relapsing disease, stable disease, and advanced disability populations.

By data source, the market includes patient registries, hospital databases, electronic health records, laboratory databases, insurance claims, and population-based epidemiological studies.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, contract research organizations, government agencies, and healthcare consulting firms.

Technological advancements in artificial intelligence, predictive analytics, digital health platforms, biomarker research, and real-world evidence systems are enhancing patient identification, disease surveillance, and long-term epidemiological forecasting.

Regional Insights

North America remains the leading market for NMOSD patient population analysis due to advanced diagnostic infrastructure, widespread antibody testing, established patient registries, and extensive rare disease research programs.

Europe represents another significant market supported by collaborative neurological research networks, comprehensive healthcare systems, and expanding epidemiological surveillance initiatives.

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to improving healthcare infrastructure, increasing access to antibody testing, rising awareness of autoimmune neurological disorders, and expanding clinical research activities. Countries including Japan, China, South Korea, and India continue to strengthen rare disease diagnosis and patient registry programs.

Latin America and the Middle East & Africa are gradually improving epidemiological surveillance through better diagnostic capabilities, expanding healthcare access, and participation in international research collaborations.

Competitive Landscape

The competitive landscape includes epidemiology research organizations, healthcare analytics providers, patient registry operators, pharmaceutical companies, biotechnology firms, academic research institutions, and healthcare consulting organizations.

Industry participants continue to invest in real-world evidence generation, digital epidemiology platforms, biomarker research, and advanced healthcare analytics. Strategic collaborations among pharmaceutical companies, academic centers, patient advocacy groups, and government agencies are improving patient identification and strengthening epidemiological research.

Growing adoption of targeted biologic therapies is also increasing demand for highly detailed patient segmentation and long-term population forecasting.

Future Outlook

The future NMOSD patient population analysis market is expected to be driven by continued expansion of antibody testing, increasing adoption of precision medicine, broader implementation of digital health technologies, and greater integration of artificial intelligence into epidemiological research.

Advances in genomic medicine, biomarker discovery, and real-world evidence platforms are expected to improve patient identification, refine disease classification, and enhance long-term forecasting accuracy.

As awareness continues to increase worldwide, more comprehensive patient databases will support clinical development, healthcare planning, reimbursement strategies, and commercialization of emerging therapies.

Conclusion

The global Neuromyelitis Optica patient population analysis market is poised for sustained growth through 2035, supported by expanding diagnostic capabilities, increasing disease awareness, growing investment in rare neurological disease research, and the rising adoption of targeted biologic therapies. While challenges related to underdiagnosis, regional variability, and limited epidemiological datasets remain, advances in antibody diagnostics, patient registries, artificial intelligence, and real-world evidence are expected to significantly enhance patient identification and long-term disease forecasting. These developments will strengthen clinical research, optimize healthcare resource allocation, and support the successful commercialization of innovative NMOSD therapies.

Key Benefits of this Report

Insightful Analysis: Comprehensive evaluation of global NMOSD prevalence, incidence, diagnosed patient populations, and epidemiological trends.
Competitive Landscape: Understand regional disease burden, demographic characteristics, and evolving patient registry initiatives.
Market Drivers and Future Trends: Assess factors influencing patient identification, diagnosis rates, and future population growth.
Actionable Recommendations: Support healthcare planning, clinical trial recruitment, commercialization strategies, and investment decisions.
Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, consultants, investors, and policymakers.

What Businesses Use Our Reports For

Patient population forecasting, epidemiological assessment, clinical trial planning, market opportunity evaluation, healthcare resource planning, rare disease strategy development, investment analysis, commercialization planning, and reimbursement assessment.

Report Coverage

Historical data from 2021 to 2025, Base year 2025, and Forecast years from 2026 to 2035
Global, regional, and country-level patient population analysis and forecasts
Prevalence, incidence, diagnosed patient population, antibody status, and demographic segmentation
Disease-stage assessment, epidemiological trends, and regional burden analysis
Competitive intelligence, patient registry evaluation, and future market opportunity outlook.

1. Executive Summary

1.1 Market Snapshot
1.2 Key Epidemiology Insights
1.3 Patient Population Overview
1.4 Key Growth Drivers and Challenges
1.5 Treatment Landscape Highlights
1.6 Competitive Overview
1.7 Future Outlook

2. Disease & Epidemiology Analysis

2.1 Overview of Neuromyelitis Optica
- 2.1.1 Disease Definition
- 2.1.2 Historical Evolution and Classification
- 2.1.3 Pathophysiology
- 2.1.4 Disease Burden
2.2 Disease Classification
- 2.2.1 AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- 2.2.2 AQP4-IgG Negative NMOSD
- 2.2.3 MOG Antibody-Associated Disease (MOGAD) Differential Diagnosis
- 2.2.4 Seronegative NMOSD
2.3 Etiology and Risk Factors
- 2.3.1 Genetic Factors
- 2.3.2 Autoimmune Associations
- 2.3.3 Environmental Factors
- 2.3.4 Gender and Age Distribution
2.4 Clinical Manifestations
- 2.4.1 Optic Neuritis
- 2.4.2 Acute Myelitis
- 2.4.3 Area Postrema Syndrome
- 2.4.4 Brainstem and Cerebral Syndromes
2.5 Diagnostic Criteria and Biomarkers
- 2.5.1 International Consensus Diagnostic Criteria
- 2.5.2 Aquaporin-4 Antibody Testing
- 2.5.3 MOG Antibody Testing
- 2.5.4 Imaging and Laboratory Assessment
2.6 Global Epidemiology Analysis
- 2.6.1 Prevalence Analysis
- 2.6.2 Incidence Analysis
- 2.6.3 Diagnosed Patient Population
- 2.6.4 Treated Patient Population
- 2.6.5 Gender-Based Patient Population
- 2.6.6 Age-Based Patient Population
- 2.6.7 AQP4-IgG Positive Patient Population
- 2.6.8 AQP4-IgG Negative Patient Population
- 2.6.9 Relapsing versus Monophasic Disease Population

3. Market Dynamics

3.1 Market Drivers
- 3.1.1 Increasing Disease Awareness
- 3.1.2 Improved Diagnostic Capabilities
- 3.1.3 Expansion of Targeted Biologic Therapies
- 3.1.4 Growing Healthcare Expenditure
3.2 Market Restraints
- 3.2.1 Rare Disease Patient Pool
- 3.2.2 High Treatment Costs
- 3.2.3 Delayed Diagnosis
- 3.2.4 Limited Access in Emerging Markets
3.3 Market Opportunities
- 3.3.1 Complement Pathway Inhibitors
- 3.3.2 FcRn Inhibitors
- 3.3.3 Personalized Medicine Approaches
- 3.3.4 Emerging Biomarkers
3.4 Porter's Five Forces Analysis
3.5 PESTLE Analysis

4. Commercial & Market Access

4.1 Reimbursement Landscape
4.2 Pricing Analysis of Approved Therapies
4.3 Health Technology Assessment Trends
4.4 Market Access Challenges
4.5 Rare Disease Funding Programs
4.6 Patient Assistance Programs
4.7 Distribution and Supply Chain Trends

5. Innovation & Pipeline Landscape

5.1 Overview of Pipeline Landscape
5.2 Pipeline Analysis by Development Stage
- 5.2.1 Phase I
- 5.2.2 Phase II
- 5.2.3 Phase III
5.3 Pipeline Analysis by Mechanism of Action
- 5.3.1 Complement Inhibitors
- 5.3.2 Anti-CD19 Therapies
- 5.3.3 IL-6 Receptor Inhibitors
- 5.3.4 FcRn Inhibitors
- 5.3.5 B-cell Targeting Therapies
- 5.3.6 Novel Immunomodulators
5.4 Pipeline Analysis by Modality
- 5.4.1 Monoclonal Antibodies
- 5.4.2 Recombinant Proteins
- 5.4.3 Small Molecules
- 5.4.4 Cell-Based Therapies
5.5 Clinical Trial Landscape
5.6 Innovation Trends
5.7 Emerging Technologies and Future Therapies

6. Treatment Landscape

6.1 Current Treatment Algorithm
6.2 Acute Attack Management
- 6.2.1 Corticosteroids
- 6.2.2 Plasma Exchange
- 6.2.3 Intravenous Immunoglobulin
6.3 Maintenance Therapy
- 6.3.1 Complement Inhibitors
- 6.3.2 Anti-CD19 Therapies
- 6.3.3 IL-6 Receptor Inhibitors
- 6.3.4 B-cell Depleting Therapies
- 6.3.5 Immunosuppressive Agents
6.4 Approved Therapies Overview
- 6.4.1 Soliris (Eculizumab)
- 6.4.2 Ultomiris (Ravulizumab-cwvz)
- 6.4.3 Uplizna (Inebilizumab-cdon)
- 6.4.4 Enspryng (Satralizumab-mwge)
6.5 Unmet Needs and Treatment Gaps

7. Global Neuromyelitis Optica Patient Population Analysis Size & Forecast

7.1 Market Overview
7.2 Historical Market Size Analysis
7.3 Forecast Market Size Analysis
7.4 Market Growth Rate Analysis
7.5 Epidemiology-Based Market Forecast
7.6 Treatment Adoption Forecast
7.7 Scenario Analysis

8. Global Neuromyelitis Optica Patient Population Analysis Segmentation

8.1 By Treatment Type
- 8.1.1 Anti-CD19 Therapies
- 8.1.2 IL-6 Receptor Inhibitors
- 8.1.3 Immunosuppressants
- 8.1.4 Others
8.2 By Disease Type
- 8.2.1 AQP4-IgG Positive NMOSD
- 8.2.2 AQP4-IgG Negative NMOSD
8.3 By Gender
- 8.3.1 Female
- 8.3.2 Male
8.4 By Age Groups
- 8.4.1 Pediatric
- 8.4.2 Adults
- 8.4.3 Elderly
8.5 By Care Setting
- 8.5.1 Hospitals
- 8.5.2 Specialty Clinics
- 8.5.3 Others

9. Geographical Analysis

9.1 North America
- 9.1.1 Market Size and Growth
- 9.1.2 Epidemiology Trends
- 9.1.3 Regulatory Overview
- 9.1.4 Competitive Intensity
9.2 Europe
- 9.2.1 Market Size and Growth
- 9.2.2 Epidemiology Trends
- 9.2.3 Regulatory Overview
- 9.2.4 Competitive Intensity
9.3 Asia-Pacific
- 9.3.1 Market Size and Growth
- 9.3.2 Epidemiology Trends
- 9.3.3 Regulatory Overview
- 9.3.4 Competitive Intensity
9.4 Latin America
- 9.4.1 Market Size and Growth
- 9.4.2 Epidemiology Trends
- 9.4.3 Regulatory Overview
- 9.4.4 Competitive Intensity
9.5 Middle East & Africa
- 9.5.1 Market Size and Growth
- 9.5.2 Epidemiology Trends
- 9.5.3 Regulatory Overview
- 9.5.4 Competitive Intensity

10. Key Countries Analysis

10.1 United States
10.2 Canada
10.3 Germany
10.4 United Kingdom
10.5 France
10.6 Italy
10.7 Spain
10.8 China
10.9 Japan
10.10 India
10.11 South Korea
10.12 Australia
10.13 Brazil
10.14 Mexico
10.15 Saudi Arabia
10.16 South Africa

11. Regulatory & Policy Landscape

11.1 Regulatory Overview for Rare Autoimmune Diseases
11.2 United States FDA Framework
11.3 European Medicines Agency (EMA) Framework
11.4 Japan PMDA Framework
11.5 India CDSCO Framework
11.6 China NMPA Framework
11.7 Orphan Drug Regulations
11.8 Accelerated Approval Pathways
11.9 Pharmacovigilance Requirements

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Competitive Benchmarking
12.3 Product Portfolio Analysis
12.4 Pipeline Competitiveness Analysis
12.5 Strategic Collaborations and Licensing Agreements
12.6 Mergers and Acquisitions
12.7 Recent Developments

13. Company Profiles

13.1 Alexion Pharmaceuticals
- 13.1.1 Company Overview
- 13.1.2 Approved Products: Soliris (Eculizumab), Ultomiris (Ravulizumab-cwvz)
- 13.1.3 Key Indications
- 13.1.4 Pipeline Overview
13.2 AstraZeneca
- 13.2.1 Company Overview
- 13.2.2 Rare Disease Portfolio
- 13.2.3 Key Indications
- 13.2.4 Pipeline Overview
13.3 Amgen Inc.
- 13.3.1 Company Overview
- 13.3.2 Approved Product: Uplizna (Inebilizumab-cdon)
- 13.3.3 Key Indications
- 13.3.4 Pipeline Overview
13.4 Roche Holding AG
- 13.4.1 Company Overview
- 13.4.2 Approved Product: Enspryng (Satralizumab)
- 13.4.3 Key Indications
- 13.4.4 Pipeline Overview
13.5 Chugai Pharmaceutical Co., Ltd.
- 13.5.1 Company Overview
- 13.5.2 Approved Product: Enspryng (Satralizumab)
- 13.5.3 Key Indications
- 13.5.4 Pipeline Overview
13.6 Tanabe Pharma Corporation
- 13.6.1 Company Overview
- 13.6.2 Immunology Portfolio
- 13.6.3 Key Indications
- 13.6.4 Pipeline Overview
13.7 argenx SE
- 13.7.1 Company Overview
- 13.7.2 FcRn Inhibitor Portfolio
- 13.7.3 Key Indications
- 13.7.4 Pipeline Overview
13.8 Dianthus Therapeutics, Inc.
- 13.8.1 Company Overview
- 13.8.2 Complement Pathway Programs
- 13.8.3 Key Indications
- 13.8.4 Pipeline Overview
13.9 Novartis AG
- 13.9.1 Company Overview
- 13.9.2 Immunology Portfolio
- 13.9.3 Key Indications
- 13.9.4 Pipeline Overview
13.10 Kyverna Therapeutics, Inc.
- 13.10.1 Company Overview
- 13.10.2 Autoimmune Disease Programs
- 13.10.3 Key Indications
- 13.10.4 Pipeline Overview

14. Future Outlook

14.1 Future Epidemiology Trends
14.2 Emerging Therapeutic Paradigms
14.3 Innovation Outlook
14.4 Market Growth Opportunities
14.5 Long-Term Forecast Scenario

15. Methodology

15.1 Research Objectives
15.2 Secondary Research Methodology
15.3 Primary Research Methodology
15.4 Epidemiology Modeling Approach
15.5 Market Estimation and Forecasting Methodology
15.6 Data Validation and Triangulation
15.7 Assumptions and Limitations

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

視神經脊髓炎治療市場報告：趨勢、預測和競爭分析（至2035年）

全球視神經脊髓炎治療研發管線分析 - 2026 年（第二季洞察與臨床試驗）

全球視神經脊髓炎流行病學分析與預測 - 2026 年

2026-2035年視神經脊髓炎全球藥物定價與報銷分析

全球視神經脊髓炎市場：競爭分析（2026 年）

全球視神經脊髓炎新興療法報告：2026年第二季度

全球視神經脊髓炎治療市場：策略性洞察與預測（2026-2035 年）

全球視神經脊髓炎臨床試驗現況：趨勢與分析（2026 年版）

視神經脊髓炎市場：策略性洞察與預測（2026-2035 年）

FAQ

全球視神經脊髓炎患者人數分析與預測（2026-2035 年）